Balversa

• Balversa (erdafitinib) is an oral targeted therapy for adults with locally advanced or metastatic urothelial carcinoma.
• It is specifically indicated for patients with susceptible fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations.
• The medication functions by selectively inhibiting FGFRs, thereby disrupting cancer cell proliferation and survival pathways.
• Common side effects include hyperphosphatemia, stomatitis, and nail disorders, requiring careful monitoring.
• Dosage is individualized and requires regular ophthalmologic examinations due to potential ocular toxicity.

What is Balversa?

Balversa is the brand name for erdafitinib, an oral medication classified as a kinase inhibitor. It is a targeted therapy approved for the treatment of adults with locally advanced or metastatic urothelial carcinoma (a type of bladder cancer) that has susceptible fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations, and has progressed during or after at least one line of platinum-containing chemotherapy. This medication represents a significant advancement in personalized cancer treatment, focusing on specific genetic mutations within cancer cells.

Balversa: Uses and Mechanism of Action

Balversa is primarily used for the treatment of advanced urothelial carcinoma in patients whose tumors have specific genetic mutations. The presence of these FGFR genetic alterations is crucial for patient selection, as the drug’s efficacy is directly linked to its ability to target these specific pathways. Before initiating treatment, patients must undergo a diagnostic test to confirm the presence of these susceptible FGFR alterations.

The mechanism of action for Balversa involves its role as a selective inhibitor of fibroblast growth factor receptors (FGFRs). In certain cancers, FGFRs can be overactive or mutated, leading to uncontrolled cell growth and survival. Balversa works by binding to and inhibiting the activity of FGFR1, FGFR2, FGFR3, and FGFR4. By blocking these receptors, Balversa disrupts the signaling pathways that promote cancer cell proliferation, differentiation, and survival, ultimately leading to the inhibition of tumor growth. This targeted approach minimizes harm to healthy cells compared to traditional chemotherapy, which often affects rapidly dividing cells indiscriminately. This detailed Balversa medication information highlights its precise action against specific genetic drivers of cancer.

Balversa Side Effects and Dosage

As with most cancer treatments, Balversa can cause a range of side effects, some of which can be serious. Patients receiving Balversa require close monitoring by their healthcare team. Common side effects often include:

• Hyperphosphatemia (high levels of phosphate in the blood)
• Stomatitis (inflammation or sores in the mouth)
• Nail disorders (e.g., brittle nails, nail detachment)
• Diarrhea
• Fatigue
• Dry mouth
• Changes in liver and kidney function tests

More serious side effects can include ocular toxicities, such as central serous retinopathy (fluid accumulation under the retina) or retinal pigment epithelial detachment, which can lead to visual impairment. Therefore, regular ophthalmologic examinations, including optical coherence tomography (OCT), are mandatory before and during treatment with Balversa. The recommended starting dosage for Balversa is typically 8 mg orally once daily, with potential for dose escalation to 9 mg based on phosphate levels and tolerability. The dosage may be adjusted or interrupted based on the patient’s response to treatment and the management of side effects. It is crucial for patients to follow their doctor’s instructions precisely regarding dosage and to report any new or worsening symptoms promptly.